Association of metabolic syndrome and hidradenitis suppurativa.
暂无分享,去创建一个
G. Jemec | K. Zarchi | C. Ellervik | G. Vinding | K. Ibler | I. Miller | K. Knudsen
[1] G. Jemec,et al. The prevalence of inverse recurrent suppuration: a population‐based study of possible hidradenitis suppurativa , 2014, The British journal of dermatology.
[2] I. Hamzavi,et al. The prevalence of metabolic syndrome in patients with hidradenitis suppurativa. , 2014, Journal of the American Academy of Dermatology.
[3] T. Skaaby,et al. Quantifying cardiovascular disease risk factors in patients with psoriasis: a meta‐analysis , 2013, The British journal of dermatology.
[4] G. Jemec,et al. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. , 2013, Journal of the American Academy of Dermatology.
[5] R. Verdolini,et al. Metformin for the treatment of hidradenitis suppurativa: a little help along the way , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] B. Nordestgaard,et al. Study design, participation and characteristics of the Danish General Suburban Population Study. , 2013, Danish medical journal.
[7] P. Wolkenstein,et al. Identification of three hidradenitis suppurativa phenotypes: latent class analysis of a cross-sectional study. , 2013, The Journal of investigative dermatology.
[8] P. Stang,et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. , 2013, Journal of the American Academy of Dermatology.
[9] M. González-Gay,et al. Metabolic Syndrome in Rheumatoid Arthritis , 2013, Mediators of inflammation.
[10] T. Russo,et al. The heliotrope sign of dermatomyositis: the correct meaning of the term heliotrope. , 2012, Archives of dermatology.
[11] G. Kokolakis,et al. Increased Prevalence of Metabolic Syndrome in Patients with Acne Inversa , 2012, PloS one.
[12] G. Jemec. Clinical practice. Hidradenitis suppurativa. , 2012, The New England journal of medicine.
[13] H. Partsch,et al. Reticulate eruptions: Part 2. Historical perspectives, morphology, terminology and classification , 2011, The Australasian journal of dermatology.
[14] R. MacIsaac,et al. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. , 2011, Heart, lung & circulation.
[15] G. Jemec,et al. Psychosocial impact of hidradenitis suppurativa: a qualitative study. , 2011, Acta dermato-venereologica.
[16] J. Szepietowski,et al. Psychophysical aspects of hidradenitis suppurativa. , 2010, Acta dermato-venereologica.
[17] S. Grundy,et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.
[18] J. Shaw,et al. International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes , 2009, Diabetes Care.
[19] N J Wald,et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.
[20] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[21] B. Nordestgaard,et al. Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction , 2008, Circulation.
[22] O. Faye,et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. , 2008, Journal of the American Academy of Dermatology.
[23] H. Kurzen,et al. What causes hidradenitis suppurativa? , 2008, Experimental dermatology.
[24] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.
[25] Claude Lenfant,et al. Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[26] Daniel W. Jones,et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.
[27] J. Lapins,et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa , 2003, The British journal of dermatology.
[28] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[29] T. Valle,et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.
[30] H. Williams,et al. The natural history of hidradenitis suppurativa , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.
[31] G. Jemec,et al. Hidradenitis suppurativa ‐ characteristics and consequences , 1996, Clinical and experimental dermatology.
[32] G. Jemec,et al. The prevalence of hidradenitis suppurativa and its potential precursor lesions. , 1996, Journal of the American Academy of Dermatology.
[33] A. Weaver,et al. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. , 2013, The Journal of investigative dermatology.
[34] G. Jemec,et al. Maturation of an Idea: A Historical Perspective on the Association of Psoriasis With the Metabolic Syndrome and Cardiovascular Disease , 2012 .
[35] G. Moneta,et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .
[36] J. Mckenney,et al. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.